Total Payments
$89,191
2024 Payments
$8,059
Companies
20
Transactions
154
Medicare Patients
914
Medicare Billing
$115,040
Payment Breakdown by Category
Consulting$71,781 (80.5%)
Travel$6,097 (6.8%)
Other$4,325 (4.8%)
Food & Beverage$3,513 (3.9%)
Research$2,994 (3.4%)
Education$480.06 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $71,781 | 25 | 80.5% |
| Travel and Lodging | $6,097 | 23 | 6.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,325 | 2 | 4.8% |
| Food and Beverage | $3,513 | 46 | 3.9% |
| Unspecified | $2,994 | 4 | 3.4% |
| Education | $480.06 | 54 | 0.5% |
Payments by Type
General
$86,196
150 transactions
Research
$2,994
4 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $23,955 | 19 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $13,652 | 18 | $0 (2024) |
| Celgene Corporation | $7,064 | 6 | $0 (2019) |
| Genentech USA, Inc. | $6,637 | 6 | $0 (2024) |
| Amgen Inc. | $6,074 | 8 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $5,812 | 5 | $0 (2023) |
| Eli Lilly and Company | $5,698 | 5 | $0 (2023) |
| Genentech, Inc. | $5,144 | 5 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $4,637 | 8 | $0 (2019) |
| Merck Sharp & Dohme LLC | $4,300 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $8,059 | 4 | AstraZeneca Pharmaceuticals LP ($3,596) |
| 2023 | $4,988 | 8 | Eli Lilly and Company ($2,700) |
| 2022 | $11,023 | 10 | AstraZeneca Pharmaceuticals LP ($5,272) |
| 2021 | $3,304 | 3 | NOVARTIS PHARMACEUTICALS CORPORATION ($2,188) |
| 2020 | $11,185 | 6 | Lilly USA, LLC ($4,744) |
| 2019 | $29,557 | 56 | Lilly USA, LLC ($8,659) |
| 2018 | $5,863 | 32 | Genentech, Inc. ($5,144) |
| 2017 | $15,213 | 35 | Lilly USA, LLC ($8,640) |
All Payment Transactions
154 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/22/2024 | Genentech USA, Inc. | Itovebi (Biological) | Consulting Fee | Cash or cash equivalent | $2,280.00 | General |
| Category: BioOncology | ||||||
| 08/22/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $47.51 | General |
| Category: Oncology | ||||||
| 08/01/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 05/16/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $3,596.25 | General |
| 12/14/2023 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| 12/07/2023 | Lilly USA, LLC | — | Food and Beverage | In-kind items and services | $111.99 | General |
| 12/04/2023 | AstraZeneca Pharmaceuticals LP | — | Travel and Lodging | In-kind items and services | $144.75 | General |
| 12/04/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $115.50 | General |
| 12/04/2023 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $27.50 | General |
| 10/27/2023 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: ONCOLOGY | ||||||
| 06/29/2023 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 04/17/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $62.96 | General |
| 12/20/2022 | Eli Lilly and Company | — | Consulting Fee | Cash or cash equivalent | $2,700.00 | General |
| 12/19/2022 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $2,135.00 | General |
| 12/08/2022 | Eli Lilly and Company | — | Food and Beverage | In-kind items and services | $100.00 | General |
| 09/30/2022 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $773.25 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III STUDY TO EVALUATE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2 PRIMARY BREAST CANCER WITH RESIDUAL TUMOR PRESENT PATHOLOGICALLY IN BREAST OR AXILLARY LYMPH NODES FOLLOWING PREOPERATIVE THERAPY • Category: BioOncology | ||||||
| 09/20/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 07/19/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $13.01 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 07/03/2022 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Consulting Fee | Cash or cash equivalent | $3,082.50 | General |
| Category: Oncology | ||||||
| 06/21/2022 | Tactile Systems Technology Inc | Flexitouch Plus (Device), entre | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: PNEUMATIC COMPRESSOR | ||||||
| 06/06/2022 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $134.61 | General |
| 04/26/2022 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 11/16/2021 | NOVARTIS PHARMACEUTICALS CORPORATION | KISQALI (Drug) | Consulting Fee | Cash or cash equivalent | $2,187.50 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 02/26/2021 | F. Hoffmann-La Roche AG | Kadcyla (Biological) | — | In-kind items and services | $1,104.59 | Research |
| Study: A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III STUDY TO EVALUATE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2 PRIMARY BREAST CANCER WITH RESIDUAL TUMOR PRESENT PATHOLOGICALLY IN BREAST OR AXILLARY LYMPH NODES FOLLOWING PREOPERATIVE THERAPY • Category: BioOncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, MULTICENTER, OPEN-LABEL PHASE III STUDY TO EVALUATE EFFICACY AND SAFETY OF TRASTUZUMAB EMTANSINE VS TRASTUZUMAB AS ADJUVANT THERAPY FOR PATIENTS WITH HER2 PRIMARY BREAST CANCER WITH RESIDUAL TUMOR PRESENT PATHOLOGICALLY IN BREAST OR AXILLARY LYMPH NODES FOLLOWING PREOPERATIVE THERAPY | F. Hoffmann-La Roche AG | $1,878 | 2 |
| A Randomized, Multicenter, Open-Label Phase III Study to Evaluate Efficacy and Safety of Trastuzumab Emtansine vs Trastuzumab as Adjuvant Therapy for Patients with HER2 Primary Breast Cancer with Residual Tumor Present Pathologically in Breast or Axillary Lymph Nodes Following Preoperative Therapy | F. Hoffmann-La Roche AG | $1,116 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 215 | 322 | $99,229 | $29,378 |
| 2022 | 3 | 206 | 310 | $89,705 | $27,011 |
| 2021 | 3 | 234 | 350 | $100,474 | $32,387 |
| 2020 | 4 | 259 | 351 | $107,543 | $26,264 |
Total Patients
914
Total Services
1,333
Medicare Billing
$115,040
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 34 | 117 | $49,257 | $15,520 | 31.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 148 | 172 | $36,464 | $10,016 | 27.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 22 | $6,908 | $1,960 | 28.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $6,600 | $1,882 | 28.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 34 | 105 | $44,205 | $14,293 | 32.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 156 | 185 | $39,220 | $11,019 | 28.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 16 | 20 | $6,280 | $1,699 | 27.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 35 | 114 | $47,994 | $15,922 | 33.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 175 | 212 | $44,944 | $13,989 | 31.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 24 | 24 | $7,536 | $2,476 | 32.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 39 | 105 | $44,205 | $11,467 | 25.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 160 | 184 | $39,008 | $9,010 | 23.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 43 | 45 | $14,130 | $3,014 | 21.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 17 | 17 | $10,200 | $2,773 | 27.2% |
About Dr. Jenny Chang, MD
Dr. Jenny Chang, MD is a Hematology & Oncology healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487734810.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jenny Chang, MD has received a total of $89,191 in payments from pharmaceutical and medical device companies, with $8,059 received in 2024. These payments were reported across 154 transactions from 20 companies. The most common payment nature is "Consulting Fee" ($71,781).
As a Medicare-enrolled provider, Chang has provided services to 914 Medicare beneficiaries, totaling 1,333 services with total Medicare billing of $115,040. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Houston, TX
- Active Since 10/17/2006
- Last Updated 03/08/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1487734810
Products in Payments
- VERZENIO (Drug) $7,922
- Abraxane (Drug) $6,591
- Non-Covered Product (Drug) $5,144
- Herceptin (Biological) $4,411
- KISQALI (Drug) $4,063
- ENHERTU (Biological) $3,083
- Kadcyla (Biological) $2,994
- Itovebi (Biological) $2,280
- Reparixin (Drug) $2,184
- LYNPARZA (Drug) $2,055
- BYL719 (Drug) $1,687
- IMFINZI (Drug) $1,045
- IBRANCE (Drug) $437.04
- Enhertu (Drug) $137.30
- CYRAMZA (Drug) $100.00
- Nerlynx (Drug) $82.00
- Orserdu (Drug) $47.51
- Flexitouch Plus (Device) $42.22
- TALZENNA (Drug) $22.10
- Cresemba (Drug) $19.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Houston
Devesh Pandya, M.d, M.D
Hematology & Oncology — Payments: $1.8M
Hematology & Oncology $1.8M
Elias Jabbour, M.d, M.D
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Naval Daver, Mbbs, MBBS
Hematology & Oncology — Payments: $983,097
Hematology & Oncology $983,097
Jorge Cortes-Franco, M.d, M.D
Hematology & Oncology — Payments: $927,016
Hematology & Oncology $927,016
Dr. Luis Camacho, M.d., Mph, M.D., MPH
Hematology & Oncology — Payments: $491,819
Hematology & Oncology $491,819
Christopher Flowers, M.d, M.D
Hematology & Oncology — Payments: $320,001
Hematology & Oncology $320,001